Nucleoside Metabolic Inhibitor [EPC]

229325 reported adverse events

Drugs of this class: FLUOROURACIL AZACITIDINE DECITABINE CAPECITABINE CLOFARABINE CYTARABINE NELARABINE PENTOSTATIN (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE GEMCITABINE

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

# Side effect Count
0 DIARRHOEA 20327
1 DEATH 16682
2 NAUSEA 15080
3 FEBRILE NEUTROPENIA 12487
4 DISEASE PROGRESSION 12298
5 NEUTROPENIA 12166
6 VOMITING 11691
7 FATIGUE 10844
8 PYREXIA 10641
9 OFF LABEL USE 9856
See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY 154 0.8701
1 ACUTE MYELOID LEUKAEMIA RECURRENT 634 0.4614
2 PIK3CA-ACTIVATED MUTATION 104 0.4370
3 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 198 0.4323
4 CAECITIS 166 0.3689
5 MYELODYSPLASTIC SYNDROME TRANSFORMATION 178 0.3640
6 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 6551 0.3504
7 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 396 0.3356
8 NEUTROPENIC COLITIS 479 0.3340
9 COLORECTAL CANCER METASTATIC 360 0.3203
See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]